Real-world comparative effectiveness and safety of tofacitinib and baricitinib in patients with rheumatoid arthritis.
Naoki IwamotoShuntaro SatoShota KurushimaToru MichitsujiShinya NishihataMomoko OkamotoYoshika TsujiYushiro EndoToshimasa ShimizuRemi SumiyoshiTakahisa SuzukiAkitomo OkadaTomohiro KogaShin-Ya KawashiriKeita FujikawaTakashi IgawaToshiyuki AramakiKunihiro IchinoseMami TamaiHideki NakamuraAkinari MizokamiTomoki OriguchiYukitaka UekiKatsumi EguchiAtsushi KawakamiPublished in: Arthritis research & therapy (2021)
Our findings indicate that tofacitinib and baricitinib had comparable continuing efficacies and safety profiles. However, there is a possibility that the influence of clinical characteristics on the treatment response differs. The comparison provides useful information to the optimal use of JAK inhibitors in real-world settings.